TITLE:
Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis
AUTHORS:
Alaa Aboud
KEYWORDS:
Chronic Hepatitis C, Sofosbuvir, Pegylated INF, Ribavirin
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.7 No.1,
January
11,
2017
ABSTRACT: Purpose: The aim is evaluation of the efficacy of triple therapy of sofosbuvir, pegylated INFalpha 2a and ribavirin in
treatment of chronic hepatitis C (CHC) patients genotype
4 who have high fibrosis. Materials and Methods: Fifty HCV patients with high
fibrosis (F3 & F4) were included in the study. Results: SVR rate was 54%; non-responders rate was 12% and relapsers rate was
34%. When comparing SVR between F3 group patients and F4 group, it was 88% and 66% respectively, which means that SVR was
higher in the F3 group. Conclusion: Triple therapy including pegylated INFalpha
2a is not an ideal therapy in treatment of CHC patients genotype 4 with
cirrhosis because of low sustained virological response rates and high
incidence of side effects.